Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people notice hip pain or hip discomfort during Mounjaro treatment, and it is a question our prescribers hear fairly regularly. Hip pain on Mounjaro is not listed as a common side effect in the licensed prescribing information, so when it does appear there are usually a handful of explanations worth thinking through — from rapid changes in body weight to referred muscle ache or unrelated causes that coincide with starting treatment. As a prescription-only medicine, tirzepatide is only available following a full clinical assessment, and any new or worsening pain should always be discussed with your prescribing team.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The honest answer is: it can be either, and working out which matters. The Mounjaro Summary of Product Characteristics (the authoritative document held on the Electronic Medicines Compendium (eMC)) lists the most common side effects as gastrointestinal in nature: nausea, diarrhoea, vomiting, constipation, and related symptoms such as the gas and bloating pain some people experience on Mounjaro. Hip pain does not feature as a common or uncommon listed event.
That said, musculoskeletal complaints do turn up in post-marketing reports for GLP-1 medicines as a class, and the MHRA's Yellow Card scheme exists precisely to capture signals like this that emerge once a medicine is in wider use. Reporting anything unexpected through Yellow Card is genuinely useful — it is how safety evidence builds over time. Tirzepatide carries a Black Triangle (▼) designation, meaning the MHRA considers additional monitoring especially important at this stage of its use in the UK.
Coincidental timing is also common. People starting a new treatment are understandably more alert to their bodies, so a pre-existing hip issue that was always there can feel newly significant. Starting treatment at a higher body weight is itself associated with hip and joint strain, which means the underlying reason for the discomfort may have nothing to do with the medicine at all.
This is one of the most plausible explanations, and it is worth understanding why. Carrying excess weight loads the hip joints unevenly over years. The surrounding muscles, tendons and bursae adapt to that distribution. When weight falls relatively quickly (which it can on Mounjaro, with tirzepatide's dual GIP and GLP-1 mechanism producing some of the more substantial reductions seen in clinical trials) those soft tissues suddenly have a different job to do.
The result can be temporary aching, a sense of looseness, or unfamiliar discomfort as your gait and posture shift. It is a bit like adjusting a chair that has always been set the same way: the new position is better for you, but your muscles notice. This tends to settle as the body adapts, but it is not something to push through if the pain is sharp or stops you moving normally.
You can read more about how similar processes affect the lower limbs on our page about leg pain and Mounjaro, which covers muscle-related discomfort in that region in more detail.
If you are doing more physical activity as part of a lifestyle programme alongside treatment (which is encouraged) hip flexor and glute aches from increased walking or exercise are another ordinary explanation worth ruling in before assuming a medicine cause.
Not all hip pain is the same, and some presentations need a clinician to look at them properly. Pain that is severe and comes on suddenly, pain that follows a fall or injury, pain accompanied by fever or swelling, or pain that radiates into the groin or down the leg should not wait for a routine check-in, get in touch with your GP or call NHS 111.
If you are experiencing a broader pattern of aches and pains, it is worth knowing that back pain and hip pain can be connected, with the same postural or muscular changes sometimes driving discomfort in both areas simultaneously. Similarly, some people ask whether the nerve-related discomfort they feel in the hip region could relate to what others describe as leg-related symptoms on tirzepatide.
Persistent pain at the injection site in the thigh (a common injection location for Mounjaro) can occasionally travel up into the hip region, and some people also notice unexpected pain in other areas, including the ear, that they want to understand in the context of their Mounjaro treatment. Rotating injection sites (abdomen, thigh, and upper arm) helps reduce localised reactions. The patient information leaflet that arrives with your pen covers rotation technique; if you are unsure, your prescribing team can walk you through it.
Start by noting when it began, where exactly it is, whether it is constant or comes and goes, and what makes it better or worse. That information is genuinely useful for any clinician assessing you, and it takes five minutes to write down.
Contact your prescribing team, at nume that means our aftercare team, who are available seven days a week. Do not adjust your dose or skip a pen on the basis of pain alone; that is a decision for your prescriber. Our FAQs cover a range of symptom questions, and our contact page has the quickest ways to reach us.
For context on the broader side-effect picture, the NHS tirzepatide information page gives a clear, patient-friendly summary of what is and is not expected on treatment. If something feels serious or your gut tells you it warrants urgent attention, seek medical help straight away rather than waiting for a prescription review.
If you are not yet on treatment and are weighing up your options, our free consultation is the starting point, a GPhC-registered prescriber reviews every application personally, the same day it is submitted.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.